Haplogen and German pharma firm Bayer have entered into a collaboration to develop drug candidates for the treatment of chronic obstructive pulmonary disease (COPD) and other pulmonary diseases.
Orchard Therapeutics, a biotechnology company focused on developing gene therapies for rare diseases, has raised $150m through a Series C funding round.
Canadian specialty pharmaceutical firm Aralez Pharmaceuticals has entered into two separate agreements to sell substantially all of its assets for a total of $250m.
Clinical-stage biotechnology firm Therachon has raised $60m mezzanine financing to advance lead program in achondroplasia and expand rare disease pipeline.
Biotechnology ccompany OvaScience and clinical-stage biopharmaceutical firm Millendo Therapeutics have signed a merger agreement to create a rare endocrine disease company.
Scancell Holdings, a developer of immunotherapies to treat cancer, has expanded its research collaboration with the rheumatology unit at the Karolinska Institute Sweden.
Japanese drugmaker Takeda has partnered with biotechnology firm Ambys Medicines to pioneer therapies for the treatment of serious liver diseases.
Apexigen, a clinical-stage biopharmaceutical company engaged in the discovery and development of a new generation of antibody therapeutics for oncology, has raised $73m in Series B And Series C financings.
Teneobio and Poseida Therapeutics have entered into a new research collaboration and licensing agreement to develop novel CAR-T therapies using Teneobio’s heavy chain only domain antibodies (UniDabs).
Acadia Pharmaceuticals and Neuren Pharmaceuticals have signed an exclusive North American license agreement for the development and commercialization of trofinetide for Rett syndrome and other indications.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.